Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anticonvulsant GABA reuptake inhibitor |
| gptkbp:approvedBy |
1997
|
| gptkbp:ATCCode |
N03AG06
|
| gptkbp:brand |
gptkb:Gabitril
|
| gptkbp:CASNumber |
115103-54-3
|
| gptkbp:chemicalFormula |
C20H25NO2S
|
| gptkbp:developer |
gptkb:Novo_Nordisk
gptkb:Cephalon |
| gptkbp:eliminationHalfLife |
7-9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
tiagabine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits GABA reuptake
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
343.48 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
96%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
confusion
nausea dizziness tremor somnolence |
| gptkbp:synonym |
gptkb:tiagabine_hydrochloride
|
| gptkbp:usedFor |
epilepsy
partial seizures |
| gptkbp:bfsParent |
gptkb:4-aminobutanoic_acid
|
| gptkbp:bfsLayer |
6
|